国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

英國Enigma Diagnostics  
Enigma DiagnosticsLimited是一家總部位于英國的未上市公司，致力于為分散和即時(shí)設置開(kāi)發(fā)新一代快速分子診斷儀器平臺。

　　Enigma的創(chuàng )新型專(zhuān)有技術(shù)將實(shí)時(shí)聚合酶鏈反應的速度和靈敏度與現場(chǎng)分散與即時(shí)測試所需的簡(jiǎn)易性相結合，可以在45分鐘之內提供原始樣本的測試結果。

　　該公司正瞄準眾多價(jià)值數十億英磅的市場(chǎng)，重點(diǎn)則放在臨床和高值應用市場(chǎng)。Enigma的商業(yè)戰略是最大化其市場(chǎng)領(lǐng)先的快速診斷即時(shí)與現場(chǎng)設備與化驗平臺的持續運轉帶來(lái)的營(yíng)收，這些設備和平臺來(lái)源于該公司廣泛的已發(fā)布和提交專(zhuān)利申請的知識產(chǎn)權組合。Enigma將與一些市場(chǎng)領(lǐng)導者合作，這些市場(chǎng)領(lǐng)導者需要有全球的市場(chǎng)滲透力，并且要適當建立內部銷(xiāo)售和營(yíng)銷(xiāo)能力以指導其產(chǎn)品的分銷(xiāo)過(guò)程。

　　Enigma 擁有 Defence Science TechnologyLaboratory授予的一系列專(zhuān)利（這些專(zhuān)利體現了英國國防部 (UK Ministry ofDefence)逾15年來(lái)對研究的大力支持）的獨家許可以及美國應用生物系統公司 (Applied Biosystems) 和CeleraLicences的實(shí)時(shí)聚合酶鏈反應設備推廣的許可。Enigma的研發(fā)活動(dòng)已經(jīng)產(chǎn)生了50多個(gè)致力于實(shí)時(shí)聚合酶鏈反應和更廣泛分子技術(shù)的全球專(zhuān)利系列。這些專(zhuān)利中有許多已經(jīng)得到美國、歐盟和日本等核心商業(yè)地區的承認，并且在眾多其它關(guān)鍵地區也有范圍更廣的申請和授權。

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings. Enigma’s innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma’s commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of- care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.